Document is current

Article History

Received: 1 March 2021

Accepted: 24 March 2021

First Online: 7 April 2021

Declarations

:

: Not applicable.

: Not applicable.

: Paolo A. Ascierto (PAA): Consulting fee: BMS, Roche, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Newlinks Genetics, Genmab, Medimmune, Sindax, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandox, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore. Contracted Research: BMS, Roche, Array. Travel Support: MSD. Michael B. Atkins (MBA): Advisory Boards: BMS, Merck, Novartis, Genentech-Roche, Eisai, Werewolf, Arrowhead, Pneuma, Leads, Pyxis Oncology, Elpis, Adagene and PACT; Consultant: BMS, Merck, Novartis, Pfizer, Genentech-Roche, Exelixis, Eisai, Aveo, ImmunoCore, Iovance, Cota, Idera, Agenus, Apexigen, TRV, and Neoleuken; Stock Options: Werewolf and Pyxis Oncology. Alexander M. Eggermont (AME): Honoraria for Scientific Advisory Board or Data Monitoring Board Membership: Biocad, BioInvent, BioNTech, BMS, CatalYm, Ellipses, Forbion, GSK, IO Biotech, ISA Pharmaceuticals, Merkc&Co/MSD, Nektar, Novartis, Pfizer, Regeneron, Sellas, SkylineDX. Jeffey E. Gershenwald (JEG): has served as a consultant and/or on advisory boards for Merck, Novartis, Bristol-Myers Squibb, Regeneron, Syndax, ouutside of the current work. Jean-Jacques Grob (JJG): I have received the funding listed below from the following sources: BMS, Novartis, MSD, Pierre Fabre, Roche, Sanofi, Merck, Pfizer. Omid Hamid (OH): Consulting/Advisory Board: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Roche Genentech, GSK, Immunocore, Idera, Incyte, Janssen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, Seattle Genetics, Tempus, Zelluna; Speaker Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron; Contracted Research (For Institution): Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck-Serono, NextCure, Novartis, Pfizer, Sanofi/Regeneron, Seattle Genetics, Torque, Zelluna. Vernon K. Sondak (VKS): is a compensated consultant for Bristol Myers Squibb, Eisai, Merck, Novartis, Regeneron and Replimune. Jeffrey A. Sosman (JAS): BMS, Necktar, Iovance, Apixagen, Courvus, Amphivena, Jazz Pharmaceutical. Hussein Tawbi (HT): Receives consulting fees from Bristol-Myers-Squibb, Merck, Novartis, Genentech, and research funding to institution from Bristol-Myers-Squibb, Merck, Novartis, Genentech, Celgene, GSK. Jeffrey S. Weber (JSW): I consult for and have received less than $10,000 dollars per annum from Merck, Genentech, Astra Zeneca, GSK, Novartis, Nektar, Medivation, Celldex, Incyte, Regeneron and EMD Serono and $10–25,000 dollars from BMS for membership on Advisory Boards. I hold equity in Celldex, CytoMx and Biond. I am on scientific advisory boards for Iovance, Celldex, CytoMx, Incyte, CV6, Sellas and cCAM. I am not a member of any speaker’s bureau NYU, but not me personally received research support from BMS, Merck, GSK, Novartis and Astra Zeneca. My laboratory receives support from Mirati and NextCure. Moffitt Cancer Center filed a patent on an IPILIMUMAB biomarker that I am named on, and Biodesix filed a PD-1 patent that I was named on. Corrado Caracò (CC): nothing to declare. Iman Osman (IO): nothing to declare. Igor Puzanov (IP): Amgen-consultant fees, steering committee member KEYNOTE 265; Merck-advisory board fees; Sotio-consultant fees; Celldex-private stock ownership. Institutional Clinical Trial Support: Nektar, Idera, Oncosec, Amgen, Rgenix, Immunocore, Dynavax.